套细胞淋巴瘤中SOX11差异性表达的研究进展

Progress of differential expression of SOX11 in mantle cell lymphoma

套细胞淋巴瘤（MCL）中CCND1的过表达以及t（11；14）（q13；q32）染色体移位是其重要标志，但有部分MCL缺乏CCND1的表达。SOX11在CCND1阴性的MCL中存在过表达，可以将其作为CCND1阴性MCL的生物学标志物。SOX11是一种神经转录因子，其过表达与组蛋白修饰和DNA甲基化密切相关。SOX11差异性表达与浆细胞的分化密切相关，并且与MCL的预后和生存时间之间存在一定关系。利用SOX11 cDNA检测MCL的微小残留病灶（MRD）比传统方法更灵敏。随着对SOX11的不断深入研究，SOX11不仅可以成为MCL诊断及预后的重要依据，而且也为MCL的靶向治疗研究提供了一个新的思路。

Overexpression of CCND1 and t （11;14） （q13;q32） chromosomal translocation are important markers in mantle cell lymphoma （MCL）. However, part of MCL lacks the expression of CCND1. SOXll can be used as a biomarker for its overexpression in CCNDl-negative MCL. SOXll is a neurogenie transcription factor, and its overexpression is closely related to histone modification and DNA methylation. Differential expression of SOX11 in MCL is closely related with the plasma cell differentiation, and there is a relationship between the prognosis and survival time of MCL. SOXll eDNA is more sensitive than conventional methods for the detection of minimal residual disease （MRD）. With further research of SOX11, it will beeome an important basis of diagnosis and prognosis in MCL, and can provide a new method for targeted therapy of MCL.